Authorized purpose: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
Clinical role
Automatic aortic segmentation and landmarking to support clinician measurements and procedure planning; the qualified professional remains responsible for interpretation and patient management.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Contrast CT angiography DICOM images of the adult cardiac and/or abdominal aorta.
Who uses it?Intended users: Trained professionals responsible for patient management; results are used with other patient information and the standard of care.
What does the software produce?Output: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
What is its most important limitation?Key limitation: The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.
Clinical takeaway. Clinical role: TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
Evidence takeaway. Evidence from the reviewed source record: K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
TeraRecon Aorta.CT (1.1.0) automatically segments the aorta and labels 22 aortic anatomical landmarks from adult contrast CTA DICOM for trained professionals' review in standard-of-care planning; it does not alter the original images or provide a diagnosis and excludes the FDA-listed device/anatomy conditions.
Automatic aortic segmentation and landmarking to support clinician measurements and procedure planning; the qualified professional remains responsible for interpretation and patient management.
Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
The indication is for adults and excludes patients with a pre-existing aortic device, bicuspid aortic valve anomaly, aortic dissection, aortic rupture, or abdominal metallic devices. Motion, occluded vessels, lack of contrast, artifacts, or landmarks outside the field of view can prevent annotation or affect output. The device does not alter original input data and does not provide a diagnosis.
K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K243158 FDA evidence is a retrospective manufacturer-submitted regulatory validation. Segmentation results come from 170 adult aortic CTA studies; landmarking required 29 supplemental studies after field-of-view and artifact exclusions, so the exact unique total across endpoints is not inferred. No independent paper or trial was promoted in this timeboxed review.
DesignRetrospective cohort validation comparing automated aortic lumen and wall-to-wall segmentation with established ground truth.
Population170 adults with cardiac and/or abdominal aortic CTA, enriched for aortic dilation/aneurysm and/or aortic valve disease; at least half of ground-truth data came from US patients across three US geographic regions.
Scopeexact submission
Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158
Samplen=170
IndependenceSponsor or vendor study
K243158
Final scanner distribution was 77 Siemens, 33 GE, 35 Philips, and 25 Canon. Manufacturer-submitted FDA evidence, not an independent clinical-outcome study.
DesignRetrospective regulatory validation of 22 aortic landmark outputs against ground-truth annotations using vessel identification, distance, and bifurcation-area criteria.
PopulationThe landmarking evaluation began with the 170-study cohort and added 29 supplemental studies because 40-45% of landmarks were outside the field of view or affected by artifacts; annotatable landmarks averaged 73 per target with a minimum of 63.
Scopeexact submission
Tested versionTeraRecon Aorta.CT (1.1.0) configuration described in K243158
IndependenceSponsor or vendor study
K243158
All 22 landmarks passed the stated 80% case-wise criterion and all exact 95% confidence-interval lower bounds were at least 70%. No exact unique total across this context and the segmentation set is inferred.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K243158. This is not a comprehensive safety clearance and does not exclude family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Contrast CT angiography DICOM images of the adult cardiac and/or abdominal aorta.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact submission accepts CTA DICOM and returns DICOM result files for viewing by DICOM-compliant systems; local routing, viewer behavior, identifiers, and report ingestion require site acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact submission is a containerized application that can run on off-the-shelf hardware or on a cloud platform; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic 3D aortic lumen and wall-to-wall segmentation with 22 labeled aortic anatomical landmarks, delivered as DICOM result files viewable by DICOM-compliant systems.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact submission is a containerized application that can run on off-the-shelf hardware or on a cloud platform; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
The exact submission accepts CTA DICOM and returns DICOM result files for viewing by DICOM-compliant systems; local routing, viewer behavior, identifiers, and report ingestion require site acceptance testing.
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
Vendor-wide
Checked 2026-10-27
Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.
TeraRecon's current regulatory page describes Aorta.CT as automatic 3D aortic segmentation and landmarking from contrast CT angiography DICOM, with DICOM result files usable by DICOM-compliant systems and no alteration of original data or diagnosis. This is current product-family context, not exact-version performance evidence.
The exact FDA submission describes a containerized application on off-the-shelf hardware or a cloud platform and DICOM result output; confirm container runtime, compute, storage, routing, and upgrade behavior during local qualification.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor regulatory page, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission
No public list price or exact contract unit for K243158 was established in the reviewed official sources.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "TeraRecon Aorta.CT reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not publicly available - checked 2026-09-07 - Exact FDA submission
The FDA indication requires trained professionals and understanding of capabilities and limitations, but no exact-version curriculum, competency assessment, or support terms were established.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.